MAGE-3.A1 peptide + NA17.A2 peptide + IL-2 + IFN-α + GMCSF + imiquimod

This is an investigational multi-component cancer immunotherapy regimen combining two tumor antigen peptides (MAGE-3.A1 and NA17.A2), three immune-stimulatory cytokines (interleukin-2, interferon-alpha, granulocyte-macrophage colony-stimulating factor), and the topical immune response modifier imiquimod. The MAGE-3.A1 peptide is derived from the melanoma-associated antigen 3 (MAGE-3) and is presented by HLA-A1 molecules to activate cytotoxic T lymphocytes against tumor cells expressing this antigen[3][5][6]. NA17.A2 is another tumor-associated peptide targeting a different epitope. IL-2, IFN-alpha, and GM-CSF are cytokines that enhance T-cell proliferation, activation, dendritic cell maturation, and overall antitumor immunity. Imiquimod acts as a toll-like receptor 7 agonist to further stimulate local immune responses at the site of administration. This combination aims to induce robust cellular immunity against tumors—primarily melanoma—by promoting both specific cytotoxic T cell responses against defined tumor antigens and general immune activation.